Viking Therapeutics News

Viking Therapeutics Insider Sold Shares Worth $4,986,008, According to a Recent SEC Filing

Greg Zante, Chief Financial Officer, on May 03, 2024, sold 66,756 shares in Viking Therapeutics (VKTX) for $4,986,008. Following the Form 4 filing with the SEC, Zante has control over a total of 174,8

MT NewswiresMay 6 03:10 ET

Viking Therapeutics(VKTX.US) Officer Sells US$4.99 Million in Common Stock

$Viking Therapeutics(VKTX.US)$ Officer ZANTE GREG sold 66,756 shares of common stock on May 3, 2024 at an average price of $74.69 for a total value of $4.99 million.Source: Announcement What is statem

moomoo NewsMay 3 21:31 ET

Form 144 | Viking Therapeutics(VKTX.US) Officer Proposes to Sell 4.98 Million in Common Stocks

SEC FILLINGS DISCLOSED/ May 3, $Viking Therapeutics(VKTX.US)$ Officer ZANTE GREG intends to sell 66,756 shares of its common stock on May 3, with a total market value of approximately $4.98 million.

moomoo NewsMay 3 16:08 ET

Express News | Viking Therapeutics Shares Fall 5.2% Premarket; Amgen 'encouraged' by Its Weight-Loss Drug Interim Data

ReutersMay 3 05:20 ET

Viking Therapeutics Insider Sold Shares Worth $22,136,474, According to a Recent SEC Filing

Marianna Mancini, Chief Operating Officer, on May 01, 2024, sold 281,425 shares in Viking Therapeutics (VKTX) for $22,136,474. Following the Form 4 filing with the SEC, Mancini has control over a tota

MT NewswiresMay 3 03:05 ET

Viking Therapeutics(VKTX.US) Officer Sells US$22.14 Million in Common Stock

$Viking Therapeutics(VKTX.US)$ Officer Mancini Marianna sold 281.43K shares of common stock on May 1, 2024 at an average price of $78.6585 for a total value of $22.14 million.Source: Announcement What

moomoo NewsMay 2 22:08 ET

Viking Mergers & Acquisitions Announces Successful Acquisition of Admar Diagnostic Instruments, Inc. by Pilar Capital

TAMPA, Fla., May 2, 2024 /PRNewswire/ -- Viking Mergers & Acquisitions is pleased to announce the successful acquisition of Admar Diagnostic Instruments, Inc., also known as Admar Neuro, by Adriana M

PR NewswireMay 2 14:45 ET

Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years

Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 44.59% on an annualized basis producing an average annual return of 56.32%. Currently, Viking Therapeutics has a

BenzingaMay 1 12:00 ET

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan

BenzingaApr 30 13:35 ET

Check Out What Whales Are Doing With VKTX

Whales with a lot of money to spend have taken a noticeably bullish stance on Viking Therapeutics.Looking at options history for Viking Therapeutics (NASDAQ:VKTX) we detected 15 trades.If we consider

BenzingaApr 30 10:31 ET

Viking Therapeutics (VKTX) Gets a Buy From Truist Financial

TipRanksApr 29 07:50 ET

Is Viking Therapeutics Incredibly Undervalued?

The Motley FoolApr 28 10:30 ET

Options Corner: Viking Therapeutics Sees Financial Giants Take Bullish Stance

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics (NASDAQ:VKTX) revealed 27 unusual trades.Delving into the details,

BenzingaApr 26 14:59 ET

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Viking Therapeutics (NASDAQ:VKTX) stock is up 251% in the last year, providing strong gains for shareholders.

Simply Wall StApr 26 10:23 ET

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 Earnings Call Transcript

Yahoo FinanceApr 26 08:15 ET

Analysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Bristol-Myers Squibb (BMY)

TipRanksApr 26 07:40 ET

Buy Rating Affirmed for Viking Therapeutics Amidst Strong Clinical Progress and Strategic Moves

TipRanksApr 26 02:10 ET

Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday

Health care stocks were leaning lower pre-bell Thursday, with the Health Care Select Sector SPDR Fund (XLV) unchanged and the iShares Biotechnology ETF (IBB) down 0.1%. AstraZeneca (AZN) shares were u

MT NewswiresApr 25 09:01 ET

Express News | HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target

BenzingaApr 25 07:19 ET

Viking Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 42.56% HC Wainwright & Co. → $90 Reiterates Buy → Buy 03/27/2024 118.6% Oppenheimer $116 → $138

BenzingaApr 25 07:18 ET